Oxford Immunotec announces US FDA approval of PMA supplement for the use of the T-Cell Xtend® reagent Independent study demonstrates that T-SPOT®.TB assay outperforms TST in predicting TB disease The T-SPOT®.TB Test Now Included in New CDC Guidelines Independent peer-reviewed study demonstrates that TB contact tracing based on use of the T-SPOT®.TB assay is more cost effective Oxford Immunotec Closes Second Tranche of $26 Million Series D Financing Led by New Leaf Venture Partners New study confirms 98.9% specificity of the T-SPOT®.TB assay Oxford Immunotec announces contract with Scancell Ltd to measure T cell response in Phase I/II clinical immunotherapy trial 2010 World TB Day Oxford Immunotec Strengthens Leadership Team T-SPOT.TB is first IGRA to be Approved for Sale in Taiwan 2009 World TB Day Oxford Immunotec announces European approval and launch of T Cell Xtend™ Oxford Immunotec Announces Board Changes T-SPOT®.TB Gains FDA Premarket Approval Study Results Confirm T-SPOT®.TB Performance is Not Affected by Low CD4 Count in HIV Infected Subjects 42 Articles